
Access to clinical trials, like access to medical care, can be financially stressful. While not all trials have costs, some do, and financial stress can depend on whether a trial has any medical costs (e.g., for tests, visits, drugs), the participant has insurance that adequately covers the medical costs, the participant’s income level, and other factors, such as potentially missing work and paying for non-medical costs like travel or childcare. Many trial sponsors, sites, and research teams work to cover trial-related medical costs, reimburse participants for non-medical costs like travel and childcare, and compensate participants for their time. However, there can be gaps in coverage, reimbursement might not be in the format or time period needed by participants, and in terms of compensation for participant time, there can be impacts upon receipt of public benefits. The MRCT Center has been working independently to bring awareness to this issue, and we are also collaborating with the Equitable Access to Clinical Trials Project. No one should lose savings, income, or benefits by participating in a clinical trial.
Related Assets
- Webinar: “Mitigating Financial Toxicity for Participants in Clinical Trials: Best Practice Considerations & Recommendations for Sponsors“
- Journal of Law, Medicine and Ethics, Daniel Albert Rozenberg et al (2025) publication: Assessing Federal Policies to Reduce Economic Barriers to Clinical Trial Enrollment
- Journal of Clinical Oncology, Barksdale et al (2025) publication: “Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions”
- An IRB Resource for Participants: Costs and Payments
- An IRB Resource for Investigators and Research Teams– Practical Points to Consider: Payment to Research Participants
- Journal of Clinical and Translational Sciences, Bierer et al (2021) publication: Fair payment and just benefits to enhance diversity in clinical research
Please note: The tools listed above are living documents and will be improved with use. We welcome feedback, suggestions, useful references, resources, and concerns.
Acknowledgments
Many thanks to everyone who has so thoughtfully collaborated on these projects. Members who have chosen to be publicly acknowledged are listed in the links below, with the titles and organizational affiliations that they had at the time of the product launch. Please note that each member served in their individual capacity, and the views and findings expressed in project materials are those of the authors and do not imply endorsement or reflect the views or policies of the U.S. Food and Drug Administration or the affiliated organization or entity of any member who contributed to this work.
eact Project
See EACT Steering Group and Participating Partners here.
IRB/HRPP Toolkit
